YU63002A - Formulacija male doze entekavira i upotreba - Google Patents

Formulacija male doze entekavira i upotreba

Info

Publication number
YU63002A
YU63002A YU63002A YUP63002A YU63002A YU 63002 A YU63002 A YU 63002A YU 63002 A YU63002 A YU 63002A YU P63002 A YUP63002 A YU P63002A YU 63002 A YU63002 A YU 63002A
Authority
YU
Yugoslavia
Prior art keywords
low dose
entecavir
dose entecavir
treatment
virus infection
Prior art date
Application number
YU63002A
Other languages
English (en)
Inventor
Richard J. Colonno
Omar L. Sprockel
Abizer Harianawala
Divyakant Desai
Michael G. Fakes
Original Assignee
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26881354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU63002(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Co. filed Critical Bristol-Myers Squibb Co.
Publication of YU63002A publication Critical patent/YU63002A/sh
Publication of RS51561B publication Critical patent/RS51561B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Preparati koji sadrže malu dozu entekavira davani su na dnevnoj osnovi da se tretira infekcija virusom hepatitisa B i/ili ko-infekcije. Obezbedjene su formulacije za oralno davanje male doze entekavira. U preparat entekavira mogu biti uključene druge farmaceutski aktivne supstance ili mogu biti date odvojeno za tretman infekcije virusom hepatitisa B ili za tretman ko-inficiranih pacijenata.[Compositions containing a low dose of entecavir are administered on a daily basis to treat hepatitis B virus infection and/or co- infections. Formulations for the oral administration of a low dose of entecavir are provided. Other pharmaceutically active substances can be included in the entecavir composition or can be separately administered for the treatment of hepatitis B virus infection or for the treatment of co-infected patients.
YU63002A 2000-02-29 2001-01-26 Formulacija male doze entekavira i upotreba RS51561B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18567200P 2000-02-29 2000-02-29
US22131300P 2000-07-28 2000-07-28
PCT/US2001/002630 WO2001064221A1 (en) 2000-02-29 2001-01-26 Low dose entecavir formulation and use

Publications (2)

Publication Number Publication Date
YU63002A true YU63002A (sh) 2005-03-15
RS51561B RS51561B (sr) 2011-08-31

Family

ID=26881354

Country Status (35)

Country Link
US (1) US6627224B2 (sh)
EP (2) EP1267880B2 (sh)
JP (3) JP5140222B2 (sh)
KR (1) KR100757155B1 (sh)
AR (1) AR027965A1 (sh)
AT (1) ATE312613T1 (sh)
AU (1) AU2001229775A1 (sh)
BG (1) BG65815B1 (sh)
BR (1) BRPI0108435B8 (sh)
CA (1) CA2401569C (sh)
CO (1) CO5261593A1 (sh)
CZ (1) CZ303395B6 (sh)
DE (1) DE60115870T3 (sh)
DK (1) DK1267880T4 (sh)
EA (1) EA006181B1 (sh)
EE (1) EE05442B1 (sh)
EG (1) EG24408A (sh)
ES (1) ES2253403T5 (sh)
GE (1) GEP20053504B (sh)
HK (1) HK1048771A1 (sh)
HR (1) HRP20020649A2 (sh)
HU (1) HU230698B1 (sh)
IL (1) IL150447A0 (sh)
MX (1) MXPA02008359A (sh)
MY (1) MY127422A (sh)
NO (1) NO324014B1 (sh)
NZ (1) NZ520024A (sh)
PE (1) PE20020770A1 (sh)
PL (1) PL201411B1 (sh)
RS (1) RS51561B (sh)
SI (1) SI1267880T2 (sh)
SK (1) SK288008B6 (sh)
TW (1) TWI287988B (sh)
UA (1) UA84534C2 (sh)
WO (1) WO2001064221A1 (sh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51561B (sr) * 2000-02-29 2011-08-31 Bristol-Myers Squibb Co. Formulacija male doze entekavira i upotreba
MY131488A (en) * 2002-04-08 2007-08-30 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP1644384B1 (en) 2002-12-11 2012-10-31 Bristol-Myers Squibb Company Process and intermediates for the synthesis of entecavir
SI1583542T1 (sl) * 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
PT1708690T (pt) 2003-11-17 2016-09-19 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
BRPI0416691A (pt) * 2003-11-18 2007-01-30 Boehringer Ingelheim Int forma de preparação farmacêutica sólida
US7511139B2 (en) 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
JP4756153B2 (ja) * 2004-08-27 2011-08-24 富士製薬工業株式会社 低成分含量の錠剤の製造方法
JP2008513584A (ja) * 2004-09-23 2008-05-01 エフ エム シー コーポレーション 被覆組成物
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN101245068A (zh) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
AU2010315414B2 (en) 2009-10-28 2015-07-09 Mcneil-Ppc, Inc. Fast dissolving/disintegrating coating compositions
EA201290556A1 (ru) 2009-12-23 2013-01-30 Рациофарм Гмбх Оральная лекарственная форма, включающая энтекавир
DE102009060194A1 (de) 2009-12-23 2011-06-30 ratiopharm GmbH, 89079 Orale Darreichungsform umfassend Entecavir
US9168269B2 (en) 2010-02-18 2015-10-27 The Trustees Of Princeton University Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals
MX2012011298A (es) 2010-03-31 2012-11-06 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico.
WO2012048455A1 (zh) * 2010-10-12 2012-04-19 武汉大学 一种抗病毒透皮吸收贴片及其制备方法
EP2508172A1 (en) 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
KR101594820B1 (ko) * 2011-06-16 2016-02-17 건일제약 주식회사 엔테카비르를 함유하는 미립구 및 이의 제조방법
KR101439635B1 (ko) 2011-11-01 2014-09-11 대원제약주식회사 안정성이 향상된 엔테카비어를 함유하는 약학적 조성물 및 그 제조방법
CA2881119A1 (en) * 2011-11-14 2013-05-23 Hetero Research Foundation Fast release solid oral compositions of entecavir
EP2644196B1 (en) * 2012-03-26 2019-09-18 Arven Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of Entecavir
EP2644197A1 (en) * 2012-03-26 2013-10-02 Sanovel Ilac Sanayi ve Ticaret A.S. Novel Pharmaceutical Compositions of Entecavir
KR101285008B1 (ko) * 2012-04-18 2013-07-10 제일약품주식회사 저용량 엔테카비어의 경구투여 제제의 제조방법
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
CN103908436B (zh) * 2012-12-29 2016-02-10 安徽贝克生物制药有限公司 一种速释型恩替卡韦组合物
KR101512895B1 (ko) 2013-08-09 2015-04-16 대화제약 주식회사 엔테카비어를 포함하는 약학적 조성물의 제조방법
WO2015194923A1 (ko) * 2014-06-20 2015-12-23 주식회사 씨티씨바이오 엔테카비르를 유효성분으로 포함하는 약학 제제 및 이의 제조방법
WO2017057147A1 (ja) 2015-09-30 2017-04-06 株式会社ダイセル 易服用性固形製剤用粒子組成物及び該粒子組成物を含む易服用性固形製剤
KR20230112817A (ko) 2022-01-21 2023-07-28 한림대학교 산학협력단 피루브산 및 pdk 억제제를 포함하는 뇌질환의 예방 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836618A (en) * 1971-12-23 1974-09-17 American Home Prod Process for the uniform distribution of a drug on a granulated base
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4489026A (en) † 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US4631284A (en) * 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
JPH08208478A (ja) * 1994-10-14 1996-08-13 Japan Energy Corp 抗エイズ薬製剤およびその製造方法
PT929294E (pt) * 1996-04-04 2003-11-28 Felix Specht Processo para a preparacao de sistemas em po fluidos e/ou directamente compressiveis de baixa dosagem
WO1998009964A1 (en) 1996-09-03 1998-03-12 Bristol-Myers Squibb Company IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE
ES2531928T3 (es) * 1998-08-10 2015-03-20 Novartis Ag Beta-L-2'-desoxi-nucleósidos para el tratamiento de la hepatitis B
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GB9820420D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820417D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820416D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
RS51561B (sr) * 2000-02-29 2011-08-31 Bristol-Myers Squibb Co. Formulacija male doze entekavira i upotreba

Also Published As

Publication number Publication date
EE05442B1 (et) 2011-08-15
ATE312613T1 (de) 2005-12-15
JP2015178523A (ja) 2015-10-08
TWI287988B (en) 2007-10-11
BR0108435A (pt) 2004-06-15
PL201411B1 (pl) 2009-04-30
PE20020770A1 (es) 2002-09-06
ES2253403T5 (es) 2010-04-22
DE60115870D1 (de) 2006-01-19
SI1267880T1 (sl) 2006-06-30
JP5921746B2 (ja) 2016-05-24
NO20024099L (no) 2002-08-28
BRPI0108435B8 (pt) 2021-05-25
WO2001064221A1 (en) 2001-09-07
IL150447A0 (en) 2002-12-01
HRP20020649A2 (en) 2004-12-31
EP1642582A1 (en) 2006-04-05
UA84534C2 (uk) 2008-11-10
BRPI0108435B1 (pt) 2019-02-05
AU2001229775A1 (en) 2001-09-12
SK11652002A3 (sk) 2003-09-11
DE60115870T2 (de) 2006-08-17
US6627224B2 (en) 2003-09-30
GEP20053504B (en) 2005-05-10
CO5261593A1 (es) 2003-03-31
NZ520024A (en) 2005-03-24
EE200200484A (et) 2004-04-15
JP5140222B2 (ja) 2013-02-06
RS51561B (sr) 2011-08-31
DE60115870T3 (de) 2010-07-29
NO324014B1 (no) 2007-07-30
PL366102A1 (en) 2005-01-24
CZ303395B6 (cs) 2012-08-29
DK1267880T4 (da) 2010-05-17
KR100757155B1 (ko) 2007-09-07
SI1267880T2 (sl) 2010-04-30
EA006181B1 (ru) 2005-10-27
HK1048771A1 (zh) 2003-04-17
SK288008B6 (sk) 2012-10-02
HUP0500558A2 (hu) 2005-09-28
EP1267880A1 (en) 2003-01-02
KR20020082230A (ko) 2002-10-30
CA2401569A1 (en) 2001-09-07
BG65815B1 (bg) 2010-01-29
EG24408A (en) 2009-05-20
CA2401569C (en) 2009-08-18
HU230698B1 (hu) 2017-09-28
EP1267880B2 (en) 2010-01-20
NO20024099D0 (no) 2002-08-28
JP2004503467A (ja) 2004-02-05
ES2253403T3 (es) 2006-06-01
MXPA02008359A (es) 2003-02-12
DK1267880T3 (da) 2006-03-06
HUP0500558A3 (en) 2012-08-28
AR027965A1 (es) 2003-04-16
EP1267880B1 (en) 2005-12-14
US20010033864A1 (en) 2001-10-25
EA200200812A1 (ru) 2003-12-25
JP2012255017A (ja) 2012-12-27
BG106905A (bg) 2003-04-30
MY127422A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
YU63002A (sh) Formulacija male doze entekavira i upotreba
GEP20053473B (en) High Potency Dihydroergotamine Compositions
MY118371A (en) Tetrahydrolipstatin containing compositions
HRP20020088B1 (en) Levodopa/carbidopa/entacapone pharmaceutical preparation
HUP0300027A2 (en) Nucleoside analogs with carboxamidine modified monocyclic base and process for their use
HUP0301121A2 (hu) Külsżleges gyógyszerkészítmények és gyógykezelések
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
GB2316004A (en) Novel formulations for transdermal delivery of pergolide
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
JP2002528502A5 (sh)
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
HUP0203303A2 (hu) Készítmény taxánok humán betegeknek történő orális adagolására
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso
JP2003514025A5 (sh)
EP1023901A4 (en) MEDICINES FOR HEPATITIS C AND THE USE THEREOF
ATE212550T1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
BR0009875A (pt) Uso de n-acetilcisteìna para a preparação de um medicamento adequado para a administração intravenosa para prevenir a carga oxidativa em pacientes que sofreram diálise
GB0018322D0 (en) Pharmaceutical compositions
AR030551A1 (es) Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante
AU2229997A (en) Pharmaceutical compositions comprising natural human alpha-interferon
BG106430A (en) Liquid mucoadhesive pharmaceutical composition
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
CA2336773A1 (en) Component b as angiogenic agent in combination with human growth factors
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten